© 2019 The Sonder Group

My first brush with Synthetic Biology, 13 years ago, was a baptism by fire, but exciting nonetheless. It was late in 2000 while I was working as part of the NewcoGen Group (a Flagship Ventures fund) where we founded a synthetic biology company called engeneOS (Engineered Genomic Operating Systems). The business plan included innovative but optimistic strategies to develop engineered genomic parts that could be assembled to provide bio-organisms with a range of novel properties. We also envisioned assembly of whole modified organisms,...

The rate at which Next Gen Systems have impacted the speed and costs of DNA sequencing has been astonishing over the last decade or so. Now there is a focus on dramatically shrinking instruments in size that may fundamentally affect how and where sequencing can be done. John Boyce first introduced the GNU Bio sequencer as the “K” cup for sequencing; a bench-top model that would be as easy to use as making a cup of coffee. The idea of being able to do DNA sequencing in every medical lab was appealing enough for Biorad to quickly acquir...

 In case you missed it, the annual international BIO conference was held in San Diego last week. As usual it attracted people from around the world, as well as a variety of headliners. Hillary Clinton spoke for an hour, voicing her support for GMO’s as well as potential government-driven agendas to foster biotech growth. Richard Branson was also a keynote speaker espousing his support for biotech’s role in developing clean energy, as well as support for world heath initiatives, such as new vaccines. Although the BIO conference is perh...

Last year was a banner year for the life science industry. The IPO market was hotter than almost anyone predicted. In fact there were 52 IPOs in the United States which collectively raised approximately $7 billion. This was a spectacular jump up from the previous year with only 16 IPOs  and $1. 1B raised. Global Mergers and acquisitions were up too from $108.9B in 2012 to $131. 8B in 2013. This includes the high visibility acquisition of Life Technologies by ThermoFisher Scientific for $13. 6B. Private financing was still challenging...

Please reload

Categories
Follow Us
  • LinkedIn Social Icon
  • Twitter Basic Square
  • Facebook Social Icon